BPC-157

Synthetic peptide fragment (derived from a protein identified in gastric juice)

This page is educational only and is not medical advice. It is not an endorsement to use this compound. See the Educational Disclaimer for details.

Quick Answer

A synthetic 15-amino-acid peptide based on a fragment of a naturally occurring protein first identified in human gastric juice. Widely discussed in online fitness/recovery communities, but its research and regulatory profile is very different from that discussion implies.

Why People Are Interested

One of the most widely discussed peptides in fitness and recovery communities, largely on the strength of animal research and a large volume of anecdotal reports about tissue and joint recovery — a useful case study in exactly the gap this Evidence Snapshot exists to make visible.

What People Hope It May Do

Faster recovery from tendon, ligament, and soft-tissue injuries, and general anti-inflammatory support — all based on preclinical/animal signals and community reports, not established human clinical evidence. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

Tendon, ligament, and muscle healing (animal models)

Gastrointestinal tissue protection/healing (animal models)

General anti-inflammatory pathways

How It May Work

Proposed (not established) mechanisms include promoting angiogenesis (new blood vessel formation) and modulating growth factor pathways involved in tissue repair — based primarily on animal-model research.

What Human Research Shows

Very limited. The only identified human data is one small, uncontrolled, retrospective case series (Lee & Padgett 2021, see Key studies) — a single clinic's chart review of 17 knee-pain patients, 12 of whom received BPC-157 alone, with 11 (91.6%) reporting improvement at 6–12 months by phone follow-up. There was no control group, no blinding, and no imaging confirmation — this is self-reported outcome data from a retrospective review, not trial-grade evidence, and should never be cited as if it were a controlled trial. A 2025 systematic review (Vasireddi et al., see Key studies) independently confirms this is the only human study identified in the sports-medicine literature; the other 35 of 36 articles it screened were preclinical.

What Preclinical Research Shows

The majority of the existing research base is rodent/animal-model studies looking at tissue healing and gut protection.

Element Evidence Snapshot™

Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.

Human ResearchVery Limited
Preclinical ResearchModerate
Clinical Trial ActivityNone Identified
Real-World InterestHigh
Regulatory StatusPreclinical-Dominant / Not Approved
Research MomentumLimited

"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.

What People Report

Real-World / Anecdotal Experience — in development. Element Health Labs hasn't yet compiled a reliable synthesis of public anecdotal reports for BPC-157. When this section is live, it will summarize commonly reported themes from public discussion, clearly separated from the scientific evidence above. Anecdotal reports are not clinical evidence, and individual experiences vary. See Real Experiences for how this is being built.

What Experts Are Saying

Curated commentary specific to BPC-157 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving BPC-157, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

Because large controlled human trials are lacking, a comprehensive human safety profile does not exist. This is itself an important safety-relevant fact to communicate, rather than an invitation to speculate about safety in either direction.

Regulatory Status

Not FDA-approved for any human use. Notably, the FDA has taken regulatory action specifically flagging BPC-157 as raising safety concerns in the context of compounding (it has been proposed/placed on lists restricting its use in compounded drug products in recent FDA guidance). It is often sold labeled "for research purposes only" — that label does not make retail sale for human consumption lawful, and this business will never frame or sell it that way.

Recent development (2026-08-17): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) to recommend adding BPC-157 to the FDA's 503A Bulks List, which would let compounding pharmacies legally use it. This is a nonbinding advisory recommendation only — the FDA has not added BPC-157 to that list, nothing about its legal status has actually changed, and it remains not FDA-approved for any human use. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. Worth noting for context: the agency's own scientists reportedly opposed the recommendation, and a majority of the panelists who voted yes reportedly have ties to the peptide industry. Full sourcing in This Week in Peptides.

What We Still Don't Know

Whether the animal-model tissue-repair signals translate to humans at all, what an appropriate human dose would even be, and long-term safety — none of which has been established through controlled human trials.

Limitations of Evidence

Predominantly animal-model evidence; human data is sparse, often low-quality, and not sufficient to support efficacy or safety claims for human use.

Key Takeaway. BPC-157 is a real area of scientific and public interest — but interest, mechanism plausibility, and proof are three different things. As of this review: human research is very limited, preclinical research is moderate, and its regulatory status is Preclinical-Dominant / Not Approved. Read the sections above — not just this summary — before forming a view, and talk to a licensed healthcare provider before making any health decision.

Keep Researching

Key Studies

Verified directly via NCBI eutils (efetch), 2026-10-11. Staresinic M, Sebecic B, Patrlj L, et al., Journal of Orthopaedic Research, 2003;21(6):976-983 (PMID 14554208): a rat Achilles-tendon transection model — BPC-157 improved biomechanical load/elasticity, functional recovery index, and microscopic repair markers (fibroblasts/collagen up, granulocytes down) vs. controls; animal-only. The only identified human study is Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine, 2021;27(4):8-13 (PMID 34324435) — a single-clinic retrospective case series, not a controlled trial (see Human evidence above for details). Independently confirmed by a 2025 systematic review: Vasireddi N, Hahamyan H, Salata MJ, et al., HSS Journal, 2025 (PMID 40756949) — screened 36 articles, found 35 preclinical and exactly 1 human study (the case series above); the review states no peer-reviewed sports-medicine-specific controlled human literature exists and recommends caution.

References

  • Staresinic M, Sebecic B, Patrlj L, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." Journal of Orthopaedic Research. 2003;21(6):976-983. PMID: 14554208. Verified via NCBI eutils, 2026-10-11.
  • Lee E, Padgett B. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435. Verified via NCBI eutils, 2026-10-11. Retrospective case series — not a controlled trial.
  • Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal. 2025. PMID: 40756949. DOI: 10.1177/15563316251355551. Verified via NCBI eutils, 2026-10-11.

Last reviewed: 2026-10-11 — Key studies/References added and independently verified, Human evidence sharpened with the specific case-series details (see above); FDA compounding-list status last re-verified 2026-08-17 (see Recent development above).

Sources. The key studies and references above are our current research notes, including dating/sourcing details where we have them — read each one for its own level of verification rather than treating this list as a uniform claim. This page will not publish claims backed by unverified or fabricated citations.
Last reviewed: 2026-10-11 — Key studies/References added and independently verified, Human evidence sharpened with the specific case-series details (see above); FDA compounding-list status last re-verified 2026-08-17 (see Recent development above).